#United States #New York #Gross Law Firm #Sarepta Therapeutics #ELEVIDYS

Attention Sarepta Therapeutics Shareholders

The Gross Law Firm has issued an important notice for investors in Sarepta Therapeutics, Inc. (NASDAQ: SRPT), reminding them of the critical deadline approaching for the lead plaintiff role in the ongoing class action lawsuit. This deadline is set for August 25, 2025, and is pivotal for those shareholders who acquired shares during the alleged wrongdoings period.

Details of the Case

According to the complaint filed, shareholders who purchased SRPT shares between June 22, 2023, and June 24, 2025, should be aware of the serious allegations against Sarepta Therapeutics. The lawsuit points to claims of materially false and misleading statements made by the company regarding its gene therapy product, ELEVIDYS, which is used to treat Duchenne Muscular Dystrophy.

Allegations Against Sarepta Therapeutics

The main allegations include:
1. Safety Risks: ELEVIDYS was claimed to pose significant safety risks to patients that were not adequately disclosed.
2. Trial Protocol Failures: The protocols used in clinical trials were criticized for failing to identify severe side effects from the treatment.
3. Regulatory Scrutiny: As a consequence of the issues above, there are concerns that Sarepta would face increased regulatory scrutiny, potentially halting ongoing trials and recruitment processes.
4. Misleading Statements: The firm argues that Sarepta misled investors regarding the safety and effectiveness of its product, causing stock price inflation based on false assurances.

The Role of Shareholders

Shareholders are encouraged to consider their legal standing in this case actively. Registering as a lead plaintiff is not a requirement to partake in any recovery associated with the lawsuit, but it might provide certain advantages in the proceedings. Once registered, shareholders will gain access to portfolio monitoring software to keep them updated on the lawsuit's progress.

Next Steps for Investors

For shareholders who fit the class period criteria, the Gross Law Firm urges swift action. Those interested in pursuing this matter should register their information as soon as possible. The registration process is straightforward and carries no cost to the shareholders. The firm also emphasizes that there is no obligation for those registering, making it a risk-free option.

Why Choose the Gross Law Firm?

The Gross Law Firm is a widely recognized class action law firm dedicated to defending investors rights. Their mission is to advocate for all individuals who have encountered losses due to misleading corporate practices. They are committed to ensuring corporate accountability and protecting the interests of investors.

Contact Information

For more details, shareholders can visit the firm’s website directly here or contact the firm using the following:

• - Phone: (646) 453-8903
• - Email: [email protected]
• - Office Address: The Gross Law Firm, 15 West 38th Street, 12th floor, New York, NY 10018

Do not miss this chance to safeguard your investment and seek possible recovery for losses incurred due to the alleged misconduct of Sarepta Therapeutics. The deadline approaches quickly and taking prompt action could be essential for many shareholders.

• ---